All serious adverse events | 28.4 | 40.0 | 24.6 |
Blood and lymphatic system disorders* | 0.5 | 1.2 | 0.3 |
Anaemias (non-haemolytic and marrow depression)† | 0.4 | 0.9 | 0.3 |
Cardiac disorders* | 1.4 | 1.9 | 1.3 |
Heart failures† | 0.4 | 0.8 | 0.3 |
Gastrointestinal disorders* | 1.4 | 1.8 | 1.2 |
General disorders and administration site conditions* | 1.5 | 1.9 | 1.4 |
Hepatobiliary disorders* | 0.4 | 0.8 | 0.3 |
Immune system disorders* | 0.2 | 0.4 | 0.2 |
Allergic conditions† | 0.2 | 0.4 | 0.2 |
Infections and infestations* | 5.5 | 6.6 | 5.1 |
Lower respiratory tract and lung infections‡ | 1.0 | 1.2 | 1.0 |
Abdominal and gastrointestinal infections‡ | 0.4 | 1.0 | 0.2 |
Sepsis, bacteraemia and viraemia‡ | 0.4 | 0.5 | 0.4 |
Bone and joint‡ | 0.1 | 0.2 | 0.1 |
Injury, poisoning and procedural complications* | 2.1 | 3.3 | 1.7 |
Musculoskeletal and connective tissue disorders* | 6.9 | 11.0 | 5.5 |
Joint disorders† | 5.3 | 8.5 | 4.3 |
Neoplasm benign, malignant, and unspecified (including cysts and polyps)* | 1.1 | 1.3 | 1.0 |
Malignancy§ | 1.1 | 1.2 | 1.0 |
Nervous system disorders* | 1.3 | 1.7 | 1.2 |
Renal and urinary disorders* | 0.5 | 0.6 | 0.5 |
Reproductive system and breast disorders* | 0.4 | 0.8 | 0.3 |
Respiratory, thoracic, and mediastinal disorders* | 1.3 | 1.3 | 1.3 |
Parenchymal lung disorders (not elsewhere classified)‡ | 0.2 | 0.3 | 0.2 |
Skin and subcutaneous tissue disorders* | 0.5 | 0.8 | 0.4 |
Surgical and medical procedures* | 1.1 | 0.9 | 1.1 |
Vascular disorders* | 0.8 | 1.0 | 0.8 |